Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Fineline Cube Feb 28, 2026
Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Fineline Cube Feb 28, 2026
Company

Eli Lilly & Co. Expands Wisconsin Manufacturing Facility with $3 Billion Investment

Fineline Cube Dec 6, 2024

US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the expansion of its...

Company

Amgen Expands Biomanufacturing Footprint in North Carolina with Second Facility

Fineline Cube Dec 6, 2024

US biotech company Amgen (NASDAQ: AMGN) has announced plans to construct a second drug substance...

Company Drug

Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral

Fineline Cube Dec 6, 2024

US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...

Company Drug

CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia

Fineline Cube Dec 6, 2024

China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...

Company

Burning Rock Ltd Reports Q3 2024 Financials with Revenue Growth and R&D Reduction

Fineline Cube Dec 5, 2024

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has released its financial results for the...

Company Deals

Novavax to Sell Czech Manufacturing Facility to Novo Nordisk for $200 Million

Fineline Cube Dec 5, 2024

US-based Novavax, Inc. (NASDAQ: NVAX) has reached an agreement to sell its manufacturing facility located...

Hospital Policy / Regulatory

China’s Health Commission Issues Guidelines to Strengthen Ties Between Healthcare and Elderly Care

Fineline Cube Dec 5, 2024

The National Health Commission, in conjunction with three other bureaus, has issued the “Notice on...

Company Drug

Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study

Fineline Cube Dec 5, 2024

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from...

Company Drug

Phanes Therapeutics’ PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer

Fineline Cube Dec 5, 2024

Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track...

Company Drug

CGeneTech’s Cetagliptin Receives NMPA Approval for Type 2 Diabetes Treatment in China

Fineline Cube Dec 5, 2024

The National Medical Products Administration (NMPA) in China has indicated on its website that CGeneTech...

Company Drug

Eisai and Biogen’s Leqembi Approved in Mexico for Early Alzheimer’s Disease Treatment

Fineline Cube Dec 5, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that their co-developed...

Company

AstraZeneca Appoints Iskra Reic as EVP, International, Amid Leon Wang’s Investigation in China

Fineline Cube Dec 5, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced the appointment of Iskra...

Company Drug

Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC

Fineline Cube Dec 5, 2024

Shanghai Escugen, a China-based biopharmaceutical company, has announced receiving the green light from the National...

Company Drug

Johnson & Johnson Submits sBLAs to FDA for Tremfya Indications in Pediatric Psoriasis and Arthritis

Fineline Cube Dec 5, 2024

Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has announced the submission of two...

Company Deals

GSK plc Expands Pipeline with Rgenta Therapeutics Partnership for RNA-Targeted Splice Modulators

Fineline Cube Dec 5, 2024

GSK plc (NYSE: GSK), a leading global pharmaceutical company, continues to bolster its pipeline through...

Company Drug

Merus N.V. Receives FDA Approval for Bizengri for NRG1+ Pancreatic and Lung Cancers

Fineline Cube Dec 5, 2024

Holland-based Merus N.V. (NASDAQ: MRUS) has announced that it has received FDA approval for its...

Company Drug

Ipsen’s Bylvay Receives NMPA Clearance for Treating Itching in PFIC Patients in China

Fineline Cube Dec 5, 2024

France-based Ipsen (EPA: IPN) has announced that it has received marketing clearance from the National...

Company Drug

Tasly Pharma Receives NMPA Approval for Generic Lioresal (Baclofen) Oral Solution

Fineline Cube Dec 5, 2024

China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received marketing approval...

Company Drug

Humanwell Healthcare’s Recombinant Plasmid Hepatocyte Growth Factor Injection Accepted for NMPA Review

Fineline Cube Dec 5, 2024

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that the National Medical Products...

Company Drug

Haisco Pharmaceutical’s HSK46575 Receives NMPA Approval for Prostate Cancer Clinical Trial

Fineline Cube Dec 5, 2024

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the receipt of clinical trial...

Posts pagination

1 … 214 215 216 … 628

Recent updates

  • Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion
  • Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA
  • Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer
  • Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis
  • Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Company Drug

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Company Drug

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.